Climb Bio (CLYM) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Climb Bio (CLYM) has outperformed Geron (GERN) over the past year, gaining 440.6% versus a loss of 22.3%. Over five years, CLYM leads with a -33.2% price change compared with -40.8% for GERN. Geron is the larger company by market cap ($560.9 million vs $539.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | GERN |
|---|---|---|
| Share price | $9.19 | $0.8707 |
| Market cap | $539.80M | $560.94M |
| 1-day change | -0.97% | -4.63% |
| YTD return | +129.75% | -34.04% |
| 1-year return | +440.59% | -22.26% |
| 5-year return | -33.21% | -40.77% |
| Forward P/E | — | 9.67 |
| EPS (TTM) | $-0.81 | $-0.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-59.85M | $-83.50M |
| 52-week high | $18.33 | $2.01 |
| 52-week low | $1.64 | $0.84 |
| Distance from 52-week high | -49.86% | -56.68% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +209.03% | +301.98% |
| Average volume | 1.38M | 13.05M |
| Shares outstanding | 58.74M | 644.24M |
| Employees | 28 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed GERN by 462.8 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
CLYM vs GERN FAQ
Which is bigger, Climb Bio or Geron?
Geron (GERN) is larger, with a market capitalization of $560.94M compared with $539.80M for Climb Bio (CLYM).
Which stock has performed better over the past year, CLYM or GERN?
CLYM returned +440.59% over the past 12 months, compared with -22.26% for GERN (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and Geron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.